Published in Cell Mol Life Sci on November 24, 2010
Complete and unidirectional conversion of human embryonic stem cells to trophoblast by BMP4. Proc Natl Acad Sci U S A (2013) 1.27
MiRNA-mediated control of HLA-G expression and function. PLoS One (2012) 1.08
HLA-G expressing DC-10 and CD4(+) T cells accumulate in human decidua during pregnancy. Hum Immunol (2012) 1.06
Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French population. PLoS One (2013) 0.99
The dual role of HLA-G in cancer. J Immunol Res (2014) 0.94
Transcriptional and posttranscriptional regulations of the HLA-G gene. J Immunol Res (2014) 0.92
Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. Am J Pathol (2012) 0.89
Roles for major histocompatibility complex glycosylation in immune function. Semin Immunopathol (2012) 0.88
Worldwide genetic variation at the 3' untranslated region of the HLA-G gene: balancing selection influencing genetic diversity. Genes Immun (2013) 0.86
Insights into HLA-G Genetics Provided by Worldwide Haplotype Diversity. Front Immunol (2014) 0.85
HLA-G as a tolerogenic molecule in transplantation and pregnancy. J Immunol Res (2014) 0.85
Controlling the Immunological Crosstalk during Conception and Pregnancy: HLA-G in Reproduction. Front Immunol (2014) 0.84
Balancing immunity and tolerance: genetic footprint of natural selection in the transcriptional regulatory region of HLA-G. Genes Immun (2014) 0.82
HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia. J Immunol Res (2014) 0.81
HLA-G UTR haplotype conservation in the Malian population: association with soluble HLA-G. PLoS One (2013) 0.80
HLA-G expression levels influence the tolerogenic activity of human DC-10. Haematologica (2015) 0.80
Polymorphic variants in exon 8 at the 3' UTR of the HLA-G gene are associated with septic shock in critically ill patients. Crit Care (2012) 0.80
What Unrelated Hematopoietic Stem Cell Transplantation in Thalassemia Taught us about Transplant Immunogenetics. Mediterr J Hematol Infect Dis (2016) 0.79
A polymorphism in HLA-G modifies statin benefit in asthma. Pharmacogenomics J (2014) 0.79
HLA-G expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med (2015) 0.79
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. PLoS One (2015) 0.79
A combination of single nucleotide polymorphisms in the 3'untranslated region of HLA-G is associated with preeclampsia. Hum Immunol (2014) 0.78
Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond. World J Gastroenterol (2014) 0.78
Human leukocyte antigen (HLA)-G gene polymorphism in patients with non-small cell lung cancer. Thorac Cancer (2015) 0.78
The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases. Front Immunol (2015) 0.78
Immunomodulatory properties of HLA-G in infectious diseases. J Immunol Res (2014) 0.78
Haplotypes of the HLA-G 3' Untranslated Region Respond to Endogenous Factors of HLA-G+ and HLA-G- Cell Lines Differentially. PLoS One (2017) 0.77
Frequency of null allele of Human Leukocyte Antigen-G (HLA-G) locus in subjects to recurrent miscarriage. Int J Reprod Biomed (Yazd) (2016) 0.77
Differential transcript profiles of MHC class Ib(Qa-1, Qa-2, and Qa-10) and Aire genes during the ontogeny of thymus and other tissues. J Immunol Res (2014) 0.77
The +3187A/G HLA-G polymorphic site is associated with polar forms and reactive reaction in leprosy. Mol Genet Genomic Med (2013) 0.76
Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2. Oncotarget (2016) 0.76
New evidence for balancing selection at the HLA-G locus in South Amerindians. Genet Mol Biol (2012) 0.76
Association of HLA-A and Non-Classical HLA Class I Alleles. PLoS One (2016) 0.75
The Attenuated Live Yellow Fever Virus 17D Infects the Thymus and Induces Thymic Transcriptional Modifications of Immunomodulatory Genes in C57BL/6 and BALB/C Mice. Autoimmune Dis (2015) 0.75
Impact of HLA-G analysis in prevention, diagnosis and treatment of pathological conditions. World J Methodol (2014) 0.75
Upregulation of Soluble HLA-G in Chronic Left Ventricular Systolic Dysfunction. J Immunol Res (2016) 0.75
Evaluation of HLA-G 14 bp Ins/Del and +3142G>C Polymorphism with Susceptibility and Early Disease Activity in Rheumatoid Arthritis. Adv Med (2016) 0.75
Immunoregulatory Role of HLA-G in Allergic Diseases. J Immunol Res (2016) 0.75
Maternal human leukocyte antigen-G (HLA-G) genetic variants associate with in utero mother-to-child transmission of HIV-1 in Black South Africans. Infect Genet Evol (2014) 0.75
The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. J Immunol Res (2016) 0.75
Possible Role of HLA-G, LILRB1 and KIR2DL4 Gene Polymorphisms in Spontaneous Miscarriage. Arch Immunol Ther Exp (Warsz) (2016) 0.75
Bronchial Epithelial Cells from Asthmatic Patients Display Less Functional HLA-G Isoform Expression. Front Immunol (2017) 0.75
Soluble human leukocyte antigen -G during pregnancy and infancy in Benin: Mother/child resemblance and association with the risk of malaria infection and low birth weight. PLoS One (2017) 0.75
Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol (2017) 0.75
Hypoxic Modulation of HLA-G Expression through the Metabolic Sensor HIF-1 in Human Cancer Cells. J Immunol Res (2017) 0.75
HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. Int J Mol Sci (2017) 0.75
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res (2006) 39.25
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature (2003) 6.48
The power of the 3' UTR: translational control and development. Nat Rev Genet (2003) 4.84
The molecular biology of the CCAAT-binding factor NF-Y. Gene (1999) 4.36
Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med (1996) 3.82
A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci U S A (1987) 2.77
Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today (1996) 2.72
Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet (2007) 2.58
Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science (2002) 2.53
MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol (2009) 2.49
A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev (1995) 2.33
Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A (2003) 2.33
The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev (2002) 2.21
The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens (2004) 2.13
Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet (2004) 2.03
Cotranscriptional mRNP assembly: from the DNA to the nuclear pore. Curr Opin Cell Biol (2005) 2.02
Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci U S A (1992) 1.95
A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet (1998) 1.84
Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A (2006) 1.78
Evolution of the MHC class I genes of a New World primate from ancestral homologues of human non-classical genes. Nature (1990) 1.68
Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood (2006) 1.65
The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol (1999) 1.64
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63
The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association. Immunity (1995) 1.63
Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol (2003) 1.60
The genetics of autoimmune diseases: a networked perspective. Curr Opin Immunol (2009) 1.56
Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood (2008) 1.56
A critical look at HLA-G. Trends Immunol (2008) 1.55
A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol (1994) 1.53
CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity (1999) 1.53
Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity (1997) 1.52
Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A (2002) 1.52
Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem (2006) 1.52
HLA-G polymorphism influences the susceptibility to HCV infection in sickle cell disease patients. Tissue Antigens (2009) 1.49
IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol (1999) 1.46
RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J (1997) 1.45
HLA-G: from biology to clinical benefits. Trends Immunol (2008) 1.45
Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol (2001) 1.42
HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci U S A (2009) 1.41
HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol (1999) 1.41
Trogocytosis-based generation of suppressive NK cells. EMBO J (2007) 1.40
The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol (2003) 1.39
The HLA-G 14 bp insertion/deletion polymorphism is a putative susceptible factor for active human cytomegalovirus infection in children. Tissue Antigens (2009) 1.39
RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity (1999) 1.39
HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics (2003) 1.38
Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol (2003) 1.36
HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol (2003) 1.33
Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci U S A (2001) 1.32
The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother (2004) 1.31
Quality control of messenger ribonucleoprotein particles in the nucleus and at the pore. Curr Opin Cell Biol (2005) 1.31
Evidence of balancing selection at the HLA-G promoter region. Hum Mol Genet (2005) 1.27
In silico analysis of microRNAS targeting the HLA-G 3' untranslated region alleles and haplotypes. Hum Immunol (2009) 1.27
Variation in the HLA-G promoter region influences miscarriage rates. Am J Hum Genet (2003) 1.27
Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics (1998) 1.24
HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update (2005) 1.24
The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol (2005) 1.21
Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha. J Biol Chem (2000) 1.21
Formation of export-competent mRNP: escaping nuclear destruction. Curr Opin Cell Biol (2005) 1.18
Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens (2003) 1.18
Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol (2000) 1.18
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol (2003) 1.17
Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol (1996) 1.16
Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens (2001) 1.15
HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res (2003) 1.13
Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun (2004) 1.13
Molecular studies of trophoblast HLA-G: polymorphism, isoforms, imprinting and expression in preimplantation embryo. Tissue Antigens (1999) 1.12
A single base-pair mutation in the 3'-untranslated region of HLA-G mRNA is associated with pre-eclampsia. Mol Hum Reprod (2008) 1.12
Monocytes and T lymphocytes in HIV-1-positive patients express HLA-G molecule. AIDS (2002) 1.11
The IMGT/HLA and IPD databases. Hum Mutat (2006) 1.10
HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci U S A (2003) 1.10
HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics (2004) 1.09
The genetic structure of 3'untranslated region of the HLA-G gene: polymorphisms and haplotypes. Genes Immun (2009) 1.07
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer (2001) 1.06
RREB-1 is a transcriptional repressor of HLA-G. J Immunol (2009) 1.05
A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem (2000) 1.05
Tolerance versus immune response -- microRNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol (2008) 1.04
Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis (2005) 1.03
Soluble HLA-G promotes Th1-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Mol Hum Reprod (2006) 1.03
Transactivation of classical and nonclassical HLA class I genes through the IFN-stimulated response element. J Immunol (1999) 1.03
Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol (2000) 1.03
HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics (2006) 1.02
The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity (2001) 1.01
HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus. Tissue Antigens (2008) 1.01
Altered HLA-G transcription in pre-eclampsia is associated with allele specific inheritance: possible role of the HLA-G gene in susceptibility to the disease. Cell Mol Life Sci (2001) 1.00
HLA-G1 protein expression is not essential for fetal survival. Placenta (1998) 1.00
Functionally active HLA-G polymorphisms are associated with the risk of heterosexual HIV-1 infection in African women. AIDS (2004) 0.99
The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B. J Immunol (1998) 0.99
The MHC-specific enhanceosome and its role in MHC class I and beta(2)-microglobulin gene transactivation. J Immunol (2001) 0.99
HLA-G gene polymorphism in human placentas: possible association of G*0106 allele with preeclampsia and miscarriage. Biol Reprod (2008) 0.98
Extraembryonic expression of the human MHC class I gene HLA-G in transgenic mice. Evidence for a positive regulatory region located 1 kilobase 5' to the start site of transcription. J Immunol (1993) 0.97
Association between human leukocyte antigen-G genotype and success of in vitro fertilization and pregnancy outcome. Tissue Antigens (2004) 0.96
The miscarriage-associated HLA-G -725G allele influences transcription rates in JEG-3 cells. Hum Reprod (2006) 0.96
Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus. Lupus (2009) 0.96
The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes (2006) 0.96
Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun (2008) 0.95
Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol (2007) 0.95
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.30
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica (2007) 3.23
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol (2010) 2.75
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol (2009) 2.49
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis (2010) 2.41
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med (2009) 2.36
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica (2006) 2.12
International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol (2010) 2.09
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica (2006) 1.99
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol (2012) 1.85
Reestablishment of damaged adult motor pathways by grafted embryonic cortical neurons. Nat Neurosci (2007) 1.83
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2009) 1.82
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol (2013) 1.80
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol (2013) 1.79
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis (2011) 1.70
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol (2009) 1.69
Thalidomide for treatment of multiple myeloma: 10 years later. Blood (2008) 1.66
Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother (2009) 1.65
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol (2012) 1.60
Performance of an agar dilution method and a Vitek 2 card for detection of inducible clindamycin resistance in Staphylococcus spp. J Clin Microbiol (2010) 1.56
Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood (2008) 1.56
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood (2010) 1.51
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica (2012) 1.47
HLA-G: from biology to clinical benefits. Trends Immunol (2008) 1.45
PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One (2007) 1.43
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica (2010) 1.42
CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood (2003) 1.40
Trogocytosis-based generation of suppressive NK cells. EMBO J (2007) 1.40
The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol (2003) 1.39
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. Cancer Res (2012) 1.38
HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res (2005) 1.35
ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood (2011) 1.35
HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol (2003) 1.33
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica (2010) 1.32
In silico analysis of microRNAS targeting the HLA-G 3' untranslated region alleles and haplotypes. Hum Immunol (2009) 1.27
Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis (2011) 1.26
Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis (2005) 1.25
International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J Clin Microbiol (2003) 1.23
CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos (2005) 1.19
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
vanA-containing Enterococcus faecium susceptible to vancomycin and teicoplanin because of major nucleotide deletions in Tn1546. J Antimicrob Chemother (2011) 1.17
CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica (2005) 1.16
Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol (2013) 1.15
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk (2010) 1.15
Prevalence and age distribution of human papillomavirus infection in a population of Inuit women in Nunavik, Quebec. Cancer Epidemiol Biomarkers Prev (2008) 1.14
Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol (2003) 1.13
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Synthetic Plasmodium-like hemozoin activates the immune response: a morphology - function study. PLoS One (2009) 1.10
Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res (2012) 1.08
High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood (2010) 1.07
Human papillomavirus type 33 polymorphisms and high-grade squamous intraepithelial lesions of the uterine cervix. J Infect Dis (2006) 1.07
Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging (2009) 1.07
RREB-1 is a transcriptional repressor of HLA-G. J Immunol (2009) 1.05
HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol (2003) 1.05
Genetic variants in nonclassical major histocompatibility complex class I human leukocyte antigen (HLA)-E and HLA-G molecules are associated with susceptibility to heterosexual acquisition of HIV-1. J Infect Dis (2005) 1.03
A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol Biol Evol (2011) 1.03
Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol (2007) 1.03
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood (2006) 1.03
HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease. J Infect Dis (2009) 1.02
HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis (2007) 1.01
Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant (2009) 1.01
Origin of Mexican Nahuas (Aztecs) according to HLA genes and their relationships with worldwide populations. Mol Immunol (2006) 1.00
Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics (2006) 1.00
APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS (2006) 1.00
Functionally active HLA-G polymorphisms are associated with the risk of heterosexual HIV-1 infection in African women. AIDS (2004) 0.99
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging (2010) 0.99
Polymorphic sites at the 3' untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French population. PLoS One (2013) 0.99
213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med (2013) 0.99
European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist (2012) 0.98
Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? Semin Hematol (2011) 0.98
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood (2003) 0.98
HLA-G gene polymorphism in human placentas: possible association of G*0106 allele with preeclampsia and miscarriage. Biol Reprod (2008) 0.98